These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 6581755)

  • 1. Imipenem versus moxalactam in the treatment of serious infections.
    Eron LJ; Hixon DL; Park CH; Goldenberg RI; Poretz DM
    Antimicrob Agents Chemother; 1983 Dec; 24(6):841-6. PubMed ID: 6581755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multiclinic randomized study of the comparative efficacy, safety and tolerance of imipenem/cilastatin and moxalactam.
    Calandra GB; Hesney M; Grad C
    Eur J Clin Microbiol; 1984 Oct; 3(5):478-87. PubMed ID: 6389126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, comparative trial of imipenem/cilastatin and moxalactam in the treatment of serious obstetric and gynecologic infections.
    Berkeley AS; Freedman KS; Hirsch JC; Ledger WJ
    Surg Gynecol Obstet; 1986 Mar; 162(3):204-8. PubMed ID: 3513346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of inoculum size on activity of cefoperazone, cefotaxime, moxalactam, piperacillin, and N-formimidoyl thienamycin (MK0787) against Pseudomonas aeruginosa.
    Corrado ML; Landesman SH; Cherubin CE
    Antimicrob Agents Chemother; 1980 Dec; 18(6):893-6. PubMed ID: 6263178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of N-formimidoyl-thienamycin in comparison to that of moxalactam and cefotaxime against gentamicin-resistant gram-negative bacteria.
    Pusztai-Markos Z; Pranada F
    Eur J Clin Microbiol; 1982 Feb; 1(1):49-51. PubMed ID: 6293811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group.
    Colardyn F; Faulkner KL
    J Antimicrob Chemother; 1996 Sep; 38(3):523-37. PubMed ID: 8889726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of N-formimidoyl thienamycin, moxalactam, and other new beta-lactam agents against Bacteroides fragilis: contribution of beta-lactamase to resistance.
    Brown JE; Del Bene VE; Collins CD
    Antimicrob Agents Chemother; 1981 Feb; 19(2):248-52. PubMed ID: 6214986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro activities of N-formimidoyl thienamycin and moxalactam against nonfermentative aerobic gram-negative rods.
    O'Donnell ED; Freimer EH; Gilardi GL; Raeder R
    Antimicrob Agents Chemother; 1982 Apr; 21(4):673-5. PubMed ID: 6211143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative clinical trial of imipenem-cilastatin (N-formimidoyl-thienamycin-dehydropeptidase inhibitor) and cefazolin.
    Marier RL; McCloskey RV; Dickenson G; Sanders CV; Aldridge KE; Hoffman T; Gutterman D; Janney A
    J Antimicrob Chemother; 1983 Dec; 12 Suppl D():133-9. PubMed ID: 6365873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled trials of double beta-lactam therapy with cefoperazone plus piperacillin in febrile granulocytopenic patients.
    Winston DJ; Ho WG; Bruckner DA; Gale RP; Champlin RE
    Am J Med; 1988 Jul; 85(1A):21-30. PubMed ID: 3041815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empirical use of imipenem as the sole antibiotic in the treatment of serious infections.
    Freimer EH; Donabedian H; Raeder R; Ribner BS
    J Antimicrob Chemother; 1985 Oct; 16(4):499-507. PubMed ID: 3864777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imipenem/cilastatin therapy of serious infections: a U.S. multicenter noncomparative trial.
    Calandra GB; Hesney M; Brown KR
    Clin Ther; 1985; 7(2):225-38. PubMed ID: 3886144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imipenem as monotherapy in the treatment of intensive care patients with severe infections.
    Dirksen MS; Wintermans RG; Boerema JB; Gimbrère JS
    J Antimicrob Chemother; 1986 Dec; 18 Suppl E():145-51. PubMed ID: 3469187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro comparative activity of moxalactam, GR 20263, and N-formimidoyl thienamycin to other beta-lactam antibiotics and tobramycin against enterobacteriaceae and staphylococci.
    Cynamon MH; Granato PA
    Chemotherapy; 1982; 28(3):204-8. PubMed ID: 6212205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of moxalactam in the treatment of serious infections due to multi-resistant organisms.
    Srinivasan S; Francke EL; Ortiz-Neu C; Prince AS; Neu HC
    Infection; 1983; 11(6):291-5. PubMed ID: 6668067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imipenem/cilastatin in the treatment of serious bacterial infections.
    Chiodini PL; Geddes AM; Smith EG; Conlon CP; Farrell ID
    Rev Infect Dis; 1985; 7 Suppl 3():S490-5. PubMed ID: 3901212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early clinical experience with imipenem-cilistatin.
    Ellis-Pegler RB; Downey D; Bremner DA
    N Z Med J; 1985 Mar; 98(775):188-91. PubMed ID: 3856762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moxalactam therapy of serious pediatric infections.
    Reed MD; Aronoff SC; Blumer JL
    Drug Intell Clin Pharm; 1984 Sep; 18(9):723-6. PubMed ID: 6479022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-blind, prospective, multicenter trial comparing ceftazidime with moxalactam in the treatment of serious gram-negative infections.
    Joshi M; Anthony WC; Tenney JH; Drusano GL; Caplan ES; Standiford HC; Henson A; Warren JW
    Antimicrob Agents Chemother; 1986 Jul; 30(1):90-5. PubMed ID: 3530128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imipenem/cilastatin versus gentamicin/clindamycin for treatment of serious bacterial infections. Report from a Scandinavian Study Group.
    Lancet; 1984 Apr; 1(8382):868-71. PubMed ID: 6143185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.